The estimated Net Worth of Cynthia L Goldenberg is at least $69.4 Million dollars as of 31 August 2017. Cynthia Goldenberg owns over 20,000 units of Immunomedics stock worth over $68,374,321 and over the last 20 years Cynthia sold IMMU stock worth over $1,051,200.
Sign up
Cynthia Goldenberg IMMU stock SEC Form 4 insiders trading
Cynthia has made over 10 trades of the Immunomedics stock since 2008, according to the Form 4 filled with the SEC. Most recently Cynthia sold 20,000 units of IMMU stock worth $252,800 on 31 August 2017.
The largest trade Cynthia's ever made was exercising 371,990 units of Immunomedics stock on 10 June 2016 worth over $967,174. On average, Cynthia trades about 57,333 units every 109 days since 2004. As of 31 August 2017 Cynthia still owns at least 778,219 units of Immunomedics stock.
You can see the complete history of Cynthia Goldenberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Cynthia Goldenberg's mailing address?
Cynthia's mailing address filed with the SEC is C/O IMMUNOMEDICS, INC., 300 AMERICAN ROAD, MORRIS PLAINS, NJ, 07950.
Insiders trading at Immunomedics
Over the last 21 years, insiders at Immunomedics have traded over $5,318,095 worth of Immunomedics stock and bought 12,330,539 units worth $195,802,181 . The most active insiders traders include Capital Advisors Llc Aghaza..., David M Goldenberg, and Cynthia L Goldenberg. On average, Immunomedics executives and independent directors trade stock every 105 days with the average trade being worth of $27,159,459. The most recent stock trade was executed by Barbara Gayle Duncan on 14 September 2020, trading 2,500 units of IMMU stock currently worth $42,400.
What does Immunomedics do?
Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
What does Immunomedics's logo look like?
Complete history of Cynthia Goldenberg stock trades at Immunomedics
Immunomedics executives and stock owners
Immunomedics executives and other stock owners filed with the SEC include:
-
Behzad Avoro Capital Adviso...,
-
Geoffrey F Cox,
Director -
Robert Forrester,
Director -
Jason Aryeh,
Director -
Harout Semerjian,
President and CEO -
Bob Oliver,
Director -
Marvin Jaffe,
Director -
Michael F. Pehl,
President and CEO -
Capital Advisors Llc Aghaza...,
-
Peter Barton Hutt,
Director -
Scott A Canute,
Director -
Khalid Islam,
Director -
Michael Garone,
CHIEF FINANCIAL OFFICER -
Brian A Markison,
Director -
Behzad Aghazadeh,
Director -
Select Advisor Llc Ven Bio,
Director -
Robert Iannone,
CHIEF MEDICAL OFFICER -
William Fricker,
Principal Accounting Officer -
Morris Rosenberg,
Chief Technology Officer -
Charles M Baum,
Director -
Bryan Ball,
Chief Quality Officer -
Barbara Gayle Duncan,
Director -
Kurt J. Andrews,
Chief Human Resources Officer -
Ivan D Horak,
EVP R&D & Ch. Scientific Off. -
Cynthia L Goldenberg,
President and CEO -
Richard R Pivirotto,
Director -
Don C Stark,
Director -
Mary E Paetzold,
Director -
Arthur S Kirsch,
Director -
Peter P. Pfreundschuh,
Chief Financial Officer -
Richard L. Sherman,
Director -
David M Goldenberg,
Chairman & Ch. Strategic Off. -
Marcella Lo Castro,
Director -
Edward T Wolynic,
Director -
Morton Coleman,
Director -
Gerard G Gorman,
VP of Finance & CFO -
Kenneth J Zuerblis,
Director -
Lorettta M Itri,
Chief Medical Officer -
Robert Azelby,
Director -
Usama Malik,
Chief Fin. & Business Officer -
Brendan Delaney,
Chief Commercial Officer -
Jared Freedberg,
Gen. Counsel & Corp. Secretary